Biochemical, clinical, genetic and metabolic studies of hyperapo-β-lipoproteinaemia

P. O. Kwiterovich

Research output: Contribution to journalArticle

Abstract

Hyperapo-β-lipoproteinaemia is a common lipoprotein disorder characterized by an elevated plasma level of the major apolipoprotein, B (apoB) of low-density β lipoproteins (LDL), combined with a low ratio of LDL cholesterol to LDL apoB. Hyperapo-β-lipoproteinaemia is due to the overproduction of LDL apoB that results from an enhanced synthesis of very low-density (pre-β) lipoprotein (VLDL) in liver. The plasma levels of high-density (α) lipoprotein (HDL) and its major apolipoprotein, A-I, are often low in hyperapo-β-lipoproteinaemia. Hyperapo-β-lipoproteinaemia is often familial and aggregates in children and adults from families with premature coronary artery disease. The precise defect(s) that cause hyperapo-β-lipoproteinaemia are not known. In a family with premature coronary artery disease and hyperapo-β-lipoproteinaemia, a mutation in codon 4046 in exon 29 of the apolipoprotein B gene, a CGG to TGG transition produced a change from arginine, a positively charged amino acid, to tryptophan, a hydrophobic amino acid, at position 4,019 of the mature apolipoprotein B protein. Decreased incorporation of free fatty acids into triglycerides of adipocytes has been described in vitro, and in vivo studies suggested a defect in clearance of postprandial lipoproteins associated with decreased uptake of plasma free fatty acids.

Original languageEnglish (US)
Pages (from-to)57-73
Number of pages17
JournalJournal of Inherited Metabolic Disease
Volume11
Issue number1 Supplement
DOIs
StatePublished - Mar 1 1988

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Biochemical, clinical, genetic and metabolic studies of hyperapo-β-lipoproteinaemia'. Together they form a unique fingerprint.

  • Cite this